SynthesisBMC cancer2018
Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Is tumor necrosis a clinical prognostic factor in hepato-biliary-pancreatic cancers? A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.Clinical epigenetics · 2021Pooled it
- Improving Clear Cell Renal Cell Carcinoma Diagnosis: Modified CT Algorithms with Simplified Heterogeneity Scoring.Annals of surgical oncology · 2026Article
- Article
- Association of renal artery variations with aggressive pathological features and poor prognosis in clear-cell renal cell carcinoma: a computed tomography-based three-dimensional reconstruction study.Quantitative imaging in medicine and surgery · 2026Article
- Predicting the prognosis of patients with renal cell carcinoma based on systemic immune inflammatory index and prognostic nutritional index.International urology and nephrology · 2025Article
- Tumor necrosis-informed prognostic nomogram for clear cell renal cell carcinoma model development and clinical validation.BMC urology · 2025Article
- Inflammation-based prognostic markers in renal cell carcinoma: insights from a 15-year experience.BMC urology · 2025Article
- A comparison of open, laparoscopic, and robotic radical nephrectomy with tumor thrombectomy from the intercontinental collaboration on renal cell carcinoma.Journal of robotic surgery · 2025Article
- Disclosing the development and focus of sequencing and omics studies in kidney neoplasm research.Discover oncology · 2025Article
- Identification of benign from malignant small renal tumors: is there a possible role of T1 mapping?Discover oncology · 2025Article
- Aggressiveness classification of clear cell renal cell carcinoma using registration-independent radiology-pathology correlation learning.Medical physics · 2025Article
- Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.Nature reviews. Urology · 2025Review
- The prognostic value of visible hematuria is only significant in T1a renal cell carcinoma: a single-center retrospective study.BMC urology · 2024Article
- Predicting the prognosis of patients with renal cell carcinoma based on the systemic immune inflammation index and prognostic nutritional index.Scientific reports · 2024Article
- Development and validation of a nomogram to predict recurrence for clinical T1/2 clear cell renal cell carcinoma patients after nephrectomy.BMC surgery · 2024Article
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Sirtuin 1, as a potential prognosis marker in clear cell renal cell carcinoma, regulates lipid metabolism and immune infiltration.Biomolecules & biomedicine · 2024Article
- Computer tomography-based shape of tumor contour and texture of tumor heterogeneity are independent prognostic indicators for clinical T1b-T2 renal cell carcinoma.World journal of urology · 2023Article
- Artificial Intelligence in Renal Cell Carcinoma Histopathology: Current Applications and Future Perspectives.Diagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor necrosis (TN) correlates with adverse outcomes in numerous solid tumors. However, its prognostic value in renal cell carcinoma (RCC) remains unclear. In this study, we performed a meta-analysis to evaluate associations between TN and cancer-specific survival (CSS), overall survival (OS), recurrence-free survival (RFS) and progression-free-survival (PFS) in RCC.
methodsElectronic searches in PubMed, EMBASE and Web of Science were conducted according to the PRISMA statement. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated to evaluate relationships between TN and RCC. A fixed- or random-effects model was used to calculate pooled HRs and 95%CIs according to heterogeneity.
resultsA total of 34 cohort studies met the eligibility criteria of this meta-analysis. The results showed that TN was significantly predictive of poorer CSS (HR = 1.37, 95% CI: 1.23-1.53, p < 0.001), OS (HR = 1.29, 95% CI: 1.20-1.40, p < 0.001), RFS (HR = 1.55, 95% CI: 1.39-1.72, p < 0.001) and PFS (HR = 1.31, 95% CI: 1.17-1.46, p < 0.001) in patients with RCC. All the findings were robust when stratified by geographical region, pathological type, staging system, number of patients, and median follow-up.
conclusionsThe present study suggests that TN is associated with CSS, OS, RFS and PFS clinical outcomes of RCC patients and may serve as a predictor of poor prognosis in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.